Neuropace Inc (NPCE)

Currency in USD
7.56
-4.46(-37.10%)
Closed·
7.20-0.36(-4.76%)
·

NPCE Earnings

Latest Release
Nov 12, 2026
EPS / Forecast
-0.10 / -0.11
Revenue / Forecast
23.1M / 27.14M
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
12/2026--/-0.114--/28.31M----Free Sign Up
09/2026-0.100/-0.10823.10M/27.14M+7.15%-14.89%Free Sign Up
06/2026-0.180/-0.21022.83M/22.56M+14.29%+1.2%Free Sign Up
03/2026-0.200/-0.22022.10M/21.65M+9.09%+2.08%Free Sign Up
12/2025-0.080/-0.18026.60M/24.39M+55.56%+9.06%Free Sign Up
09/2025-0.110/-0.20027.40M/24.31M+45%+12.71%Free Sign Up
06/2025-0.260/-0.22023.50M/23.09M-18.18%+1.78%Free Sign Up
03/2025-0.210/-0.24022.52M/21.85M+12.5%+3.07%Free Sign Up
12/2024-0.180/-0.25021.50M/20.91M+28%+2.82%Free Sign Up
09/2024-0.190/-0.27021.10M/19.07M+29.63%+10.64%Free Sign Up

All numbers in USD

Neuropace Inc Earnings Call Summary for Q3/2026

  • NeuroPace Q3 revenue of $23.1M missed estimates by 14.9%, falling 1.1% YoY; shares plunged 34.46% after-hours to $7.88 following the report.
  • Full-year 2026 guidance slashed to $91M-$92M from $99.5M-$101.5M due to sales force restructuring, account issues, and SEEG distribution exit.
  • Adjusted gross margin improved 200bps to 84.8%; company achieved first positive adjusted operating income of $0.4M versus $1.4M loss year-ago.
  • Management projects 2027 core RNS revenue growth of ~15% accelerating to 20%; expects Remote Care FDA approval in Q2 2027, IGE expansion mid-2027.
  • CEO Becker attributed Q3 weakness to concentrated large-account disruptions rather than demand decline; maintains long-term conviction in RNS growth potential.
Last Updated: 13/11/2026, 00:26
Read Full Transcript

FAQ

What Is Neuropace's Earnings Per Share (TTM)?

The Neuropace EPS (TTM) is -0.43.

When Is The Next Neuropace Earnings Date?

Neuropace will release its next earnings report on Mar 09, 2027.

What Is Neuropace’s Revenue Forecasts For Upcoming Quarters?

Neuropace’s revenue forecast is 28.31M.

How Did Neuropace React to the Company's Latest Earnings Report?

Neuropace reported a +7.15% EPS surprise and a -14.89% revenue surprise, comparing the latest report against analyst forecasts. The stock price changed by -39.62%, reflecting the market's response to the earnings results.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.